Dutch pharmaceutical company Novo Nordisk has announced plans to sell authorised generics of its insulin drug Novolog at a reduced price in the US.

The generic products will be available through the company’s US affiliate Novo Nordisk Pharma at 50% less than the list price of the existing branded versions.

The company will also introduce the $99.00 Cash Card Program for Analog Insulins.

Under the programme, up to three vials or two packs of FlexPen/FlexTouch pens of Novo Nordisk’s analogue insulins will cost $99. The amount is considered adequate to cover a month’s supply for most diabetics.

Both offerings will be available from January next year for patients with and without insurance coverage, said the company.

Novo Nordisk president Doug Langa said: “People with diabetes need more affordable options and we are going to continue doing what we can now, while also working with other healthcare stakeholders on longer-term system reform.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

“We also want to do more to make people aware of all the programmes and options across Novo Nordisk companies that may benefit them and are continuously working to ensure they are easier to access and navigate.”

The move to reduce product prices comes after the company, along with Sanofi and Eli Lilly, received letters from the US lawmakers in January seeking information on the increased costs of insulin over the recent years.

In March, Lilly revealed plans to launch a generic version of its Humalog insulin injection at a 50% reduced price under the Insulin Lispro brand. The company started selling the generic in May.

Sanofi made a similar announcement in April, reducing the cost of some of its insulin products to $99 per month.